Analysis Group Health Care Consultants to Present at ICPE 2023
Event: 39th International Conference on Pharmacoepidemiology & Therapeutic Risk Management (ICPE) Dates: 24–28 August 2023 Host: International Society for Pharmacoepidemiology (ISPE) Location: Halifax, Nova Scotia, Canada
Analysis Group, a global leader in drug safety epidemiology and regulatory real-world evidence (RWE), will present a symposium, podium presentation, and six research posters at ICPE 2023.
Chief Epidemiologist and Managing Principal Mei Sheng Duh and Vice President Marianne Cunnington will present a symposium describing a new method they developed to adjust for bias introduced by COVID-19-associated health care disruptions in RWE studies. The symposium, titled “Bias Introduced by COVID-19 Related Healthcare Disruptions in Safety and Effectiveness Studies: Proposing Methodological Solutions,” will take place on Sunday, August 27. Dr. Duh and Dr. Cunnington will be joined by speakers from GSK, the London School of Hygiene & Tropical Medicine, and the European Medicines Agency.
Additionally, Vice President Wendy Cheng and Dr. Duh will participate in the podium presentation of “Likelihood of Antimicrobial Resistance in Urinary E. coli Isolates Comparing Female Patients with Recurrent Versus Non-recurrent Uncomplicated Urinary Tract Infection in the United States” on Sunday, August 27. This study was coauthored by Analysis Group consultants and researchers from GSK and Hackensack University Medical Center. Vice President Maral DerSarkissian and Dr. Duh will present a poster on Friday, August 25, regarding interim data analysis from an FDA-required active surveillance program of COVID-19 vaccine safety by Analysis Group consultants and researchers from Pfizer and the US Veterans Health Administration, titled “Post-Emergency Use Authorization (EUA) Active Safety Surveillance Study among Individuals in the Veterans Affairs Health System Receiving Pfizer-BioNTech Coronavirus Disease 2019 (COVID-19) Vaccine.”
Further details on the symposium, podium presentation, and posters are available in our ICPE 2023 Presentation Guide.
During the conference, Dr. Cunnington, who was recently elected to ISPE’s Board, will take office as the representative for industry and service providers in Europe and Africa. Analysis Group is a proud gold sponsor of this conference.
Associated People
Marianne Cunnington
Vice PresidentDr. Cunnington has over 20 years of experience as a pharmaceutical industry epidemiologist. She specializes in the generation of real-world evidence (RWE) in support of the development and lifecycle management of pharmaceutical and vaccine products, with particular focus on regulatory risk management strategies and product benefit risk assessments. Dr. Cunnington focuses on regulatory epidemiology with design and execution of real-world post-marketing safety studies, as well as real-world studies to support the approval of new products in the context of innovative regulatory pathways. Her research expertise includes design, negotiation, and execution of real-world components of risk management plans for multiple new product submission with regulators across multiple geographies (US, UK, Europe, Japan, South Korea), post approval safety studies in the EU, post-marketing requirement and commitment studies in the US, and pregnancy registries. Prior to joining Analysis Group, Dr. Cunnington held several senior epidemiology positions within Novartis and GlaxoSmithKline (GSK). At GSK, she chaired the peer review forum for all pharmaceutical real world evidence projects, provided epidemiological expertise for the GSK’s Global Safety Board and was a managing board member of the Innovative Medicines Initiative’s public-private partnership, building an integrated European real-world data network to monitor medication safety in pregnancy. Dr. Cunnington is currently an elected board member representing European industry and service providers for the International Society of Pharmacoepidemiology.